Maria C. Trissal

Maria C. Trissal

Auto-generated profile, based on publicly available information

Maria C. Trissal

Harvard Medical School Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
EPEshini Panditharatna
Eshini Panditharatna
JMJoana G. Marques
Joana G. Marques
TWTingjian Wang
Tingjian Wang
MTMaria C. Trissal
Maria C. Trissal
ILIlon Liu
Ilon Liu
MFMariella G. Filbin
Mariella G. Filbin
Diffuse midline gliomas are uniformly fatal pediatric central nervous system cancers that are refractory to standard-of-care therapeutic modalities. The primary genetic drivers are a set of recurrent amino acid substitutions in genes encoding histone H3 (H3K27M), which are currently undruggable. These H3K27M oncohistones perturb normal chromatin architecture, resulting in an aberrant epigenetic landscape. To interrogate for epigenetic dependencies, we performed a CRISPR screen and show that patient-derived H3K27M-glioma neurospheres are dependent on core components of the mammalian BAF (SWI/SNF) chromatin remodeling complex. The BAF complex maintains glioma stem cells in a cycling, oligodendrocyte precursor cell–like state, in which genetic perturbation of the BAF catalytic subunit SMARCA4 (BRG1), as well as pharmacologic suppression, opposes proliferation, promotes progression of differentiation along the astrocytic lineage, and improves overall survival of patient-derived xenograft models. In summary, we demonstrate that therapeutic inhibition of the BAF complex has translational potential for children with H3K27M gliomas. Significance: Epigenetic dysregulation is at the core of H3K27M-glioma tumorigenesis. Here, we identify the BRG1–BAF complex as a critical regulator of enhancer and transcription factor landscapes, which maintain H3K27M glioma in their progenitor state, precluding glial differentiation, and establish pharmacologic targeting of the BAF complex as a novel treatment strategy for pediatric H3K27M glioma. See related commentary by Beytagh and Weiss, p. 2730. See related article by Mo et al., p. 2906. This article is highlighted in the In This Issue feature, p. 2711

4 April 2023
Verified
Other
Open access
EPEshini Panditharatna
Eshini Panditharatna
JMJoana G. Marques
Joana G. Marques
TWTingjian Wang
Tingjian Wang
MTMaria C. Trissal
Maria C. Trissal
ILIlon Liu
Ilon Liu
MFMariella G. Filbin
Mariella G. Filbin
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma

4 April 2023
Verified
Other
Open access
EPEshini Panditharatna
Eshini Panditharatna
JMJoana G. Marques
Joana G. Marques
TWTingjian Wang
Tingjian Wang
MTMaria C. Trissal
Maria C. Trissal
ILIlon Liu
Ilon Liu
MFMariella G. Filbin
Mariella G. Filbin
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma

4 April 2023
Verified
Other
Open access
EPEshini Panditharatna
Eshini Panditharatna
JMJoana G. Marques
Joana G. Marques
TWTingjian Wang
Tingjian Wang
MTMaria C. Trissal
Maria C. Trissal
ILIlon Liu
Ilon Liu
MFMariella G. Filbin
Mariella G. Filbin
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma

4 April 2023
Verified
Other
Open access
EPEshini Panditharatna
Eshini Panditharatna
JMJoana G. Marques
Joana G. Marques
TWTingjian Wang
Tingjian Wang
MTMaria C. Trissal
Maria C. Trissal
ILIlon Liu
Ilon Liu
MFMariella G. Filbin
Mariella G. Filbin
Supplementary Figure from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma

4 April 2023
Verified
Other
Open access
EPEshini Panditharatna
Eshini Panditharatna
JMJoana G. Marques
Joana G. Marques
TWTingjian Wang
Tingjian Wang
MTMaria C. Trissal
Maria C. Trissal
ILIlon Liu
Ilon Liu
MFMariella G. Filbin
Mariella G. Filbin
Diffuse midline gliomas are uniformly fatal pediatric central nervous system cancers that are refractory to standard-of-care therapeutic modalities. The primary genetic drivers are a set of recurrent amino acid substitutions in genes encoding histone H3 (H3K27M), which are currently undruggable. These H3K27M oncohistones perturb normal chromatin architecture, resulting in an aberrant epigenetic landscape. To interrogate for epigenetic dependencies, we performed a CRISPR screen and show that patient-derived H3K27M-glioma neurospheres are dependent on core components of the mammalian BAF (SWI/SNF) chromatin remodeling complex. The BAF complex maintains glioma stem cells in a cycling, oligodendrocyte precursor cell–like state, in which genetic perturbation of the BAF catalytic subunit SMARCA4 (BRG1), as well as pharmacologic suppression, opposes proliferation, promotes progression of differentiation along the astrocytic lineage, and improves overall survival of patient-derived xenograft models. In summary, we demonstrate that therapeutic inhibition of the BAF complex has translational potential for children with H3K27M gliomas.Significance:Epigenetic dysregulation is at the core of H3K27M-glioma tumorigenesis. Here, we identify the BRG1–BAF complex as a critical regulator of enhancer and transcription factor landscapes, which maintain H3K27M glioma in their progenitor state, precluding glial differentiation, and establish pharmacologic targeting of the BAF complex as a novel treatment strategy for pediatric H3K27M glioma.See related commentary by Beytagh and Weiss, p. 2730.See related article by Mo et al., p. 2906.This article is highlighted in the In This Issue feature, p. 2711